Karolinska Development
1.53 SEK 0%1 investor is following this company
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Revenue
-
EBIT %
-
P/E
76.5
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
KDEV
Daily low / high price
1.5 / 1.57
SEK
Market cap
413.22M SEK
Turnover
340.16K SEK
Volume
222K
Financial calendar
Interim report
30.08.2024
Interim report
15.11.2024
Annual report
14.02.2025
Interim report
30.04.2025
General meeting
15.05.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
invoX Pharma Ltd | 47.7 % | 43.9 % |
Worldwide International Investments Ltd | 10.4 % | 9.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools